Influenza News and Research

Latest Influenza News and Research

Sinovac Biotech announces receipt of Panflu vaccine distribution approval in Hong Kong

Sinovac Biotech Ltd., a leading developer and provider of vaccines in China, announced today that its wholly-owned subsidiary, Sinovac Biotech (Hong Kong) Ltd, has received the Certificate of Approval to distribute Panflu(TM) (H5N1), its H5N1 (bird flu) pandemic influenza vaccine, in Hong Kong. The certificate is valid through September 13, 2014 and thereafter will be renewable for periods of five years at a time, subject to payment of the registration fee.

14 Oct 2009

Nobilon initiates a clinical Proof of Concept trial with SCH 900795 vaccine

Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP), today announced that it has initiated a clinical Proof of Concept trial with SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.

14 Oct 2009

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, president and CEO, presented at the invitation-only World Knowledge Forum being held in Seoul, South Korea.

14 Oct 2009

Imaging as a tool to identify severe cases of H1N1

Researchers at the National Institutes of Health (NIH) have found that imaging can now be used as a tool for identifying severe cases of H1N1 and may play a key role in understanding the pathogenesis of the virus, possibly leading to earlier diagnoses of severe cases in the future, according to a study published online today in the American Journal of Roentgenology. The study will be published in the December issue of AJR.

14 Oct 2009

H1N1 patients with ARDS survive illness when treated with ECMO

Despite the severity of disease and the intensity of treatment, most patients in Australia and New Zealand who experienced respiratory failure as a result of 2009 influenza A(H1N1) and were treated with a system that adds oxygen to the patient's blood survived the disease, according to a study to appear in the November 4 issue of JAMA.

14 Oct 2009

Statewide H1N1 Vaccine Provider Registration System from Upp Technology

Supporting directives from the U.S. Centers for Disease Control and Prevention, Upp Software, a business unit of Upp Technology, Inc., has developed, delivered and now offers a Statewide H1N1 Vaccine Provider Registration System to accommodate thousands of vaccine providers' ordering and reporting needs.

14 Oct 2009

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

NanoBio Corporation today announced an award from the National Institute of Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research associated with “Innate Immune Receptors and Adjuvant Discovery.” NanoBio is the principal subcontractor for the $9.3 million contract awarded to the University of Michigan.

14 Oct 2009

Do not underestimate the serious impact of the H1N1 virus, say researchers

A research team has warned medical experts in the Northern Hemisphere not to underestimate the serious impact of the H1N1 (Swine flu) virus with a new report showing that many patients who were critically ill with the virus required prolonged life support treatment with heart-lung machines.

14 Oct 2009

Rapid rollout of H1N1 vaccines is effective in reducing infection rates according to simulation model

Early action, especially rapid rollout of vaccines, is extremely effective in reducing the attack rate of the H1N1 influenza virus, according to a simulation model of a pandemic outbreak reported in a new study in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

14 Oct 2009

American Lung Association to raise awareness about the seriousness of seasonal influenza

In the spirit of "healthy competition," the American Lung Association in Minnesota is teaming up with the Minneapolis and St. Paul Fire Departments to raise awareness about the seriousness of seasonal influenza and the importance of vaccination this year.

14 Oct 2009

New Ultra Sensitive facemasks to protect against seasonal and swine flu

BIOSAFE, Inc., a company that manufactures and sells a novel antimicrobial polymer, has announced that they are launching in specific markets outside the United States through a unique facemask treated with BIOSAFE(®). Crosstex' new BIOSAFE-treated Ultra Sensitive facemasks begin to reduce microorganisms such as MRSA, VRE, and Staph immediately upon contact, and have further proven to be effective against Influenza A strains such as seasonal flu and the novel H1N1 virus.

14 Oct 2009

Studies examine H1N1 treatment, outcome differences in Mexico, Canada

New studies suggest that "[d]eveloping countries with limited access to advanced health-care facilities may be in for a rough ride with swine [H1N1] flu and even countries with high-tech ICUs may find themselves pushed to the limit as their hospitals struggle to save gravely ill H1N1 patients," the Canadian Press reports.

14 Oct 2009

NIH awards $2.2m grant to Smiths Detection to develop a test for multiple types of influenza

Smiths Detection today announces the award of a $2.2m, two-year grant from the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health (NIH), to develop a test for multiple types of influenza.

14 Oct 2009

Study says critical illness among Canadian patients with H1N1 occurred rapidly after hospital admission

Critical illness among Canadian patients with 2009 influenza A(H1N1) occurred rapidly after hospital admission, often in young adults, and was associated with severely low levels of oxygen in the blood, multi-system organ failure, a need for prolonged mechanical ventilation, and frequent use of rescue therapies, according to a study to appear in the November 4 issue of JAMA.

13 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Massive mismanagement leads to catastrophic decline in freshwater biodiversity

The world will miss its agreed target to stem biodiversity loss by next year, according to experts convening in Cape Town for a landmark conference devoted to biodiversity science.

13 Oct 2009

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

People with psoriasis and/or psoriatic arthritis who are taking biologic or non-biologic immunosuppressive medications should receive the inactived forms of both seasonal influenza and H1N1 (swine flu) vaccines as soon as possible, according to a recommendation from the National Psoriasis Foundation.

13 Oct 2009

Health care workers raise troubling concern about H1N1 and seasonal flu vaccines

Hospital workers are asking the same questions about the safety and necessity of flu vaccines as the general public, according to a survey conducted by the American Society of Health-System Pharmacists (ASHP).

13 Oct 2009

Cox's initiative to safeguard the community at-large

Recognized as a leader in serving its customers with state-of-the-art cable, broadband and entertainment services, Cox will soon broaden its local impact by safeguarding the community at-large. On October 30, 2009, Cox will be the first and only private corporation to operate as one of three Orange County locations to conduct an Orange County Health Care Agency (OCHCA) Point-Of-Dispensing (POD) at its Rancho Santa Margarita headquarters.

13 Oct 2009

Fully-insured members of Guardian to receive 100% coverage of the administrative cost of H1N1 vaccine

The Guardian Life Insurance Company of America (Guardian), one of the largest mutual life insurers and a leading provider of employee benefits for small and mid-sized companies, today announced that it will cover 100% of the cost associated with the administration of the H1N1 vaccine for employees and their eligible dependents enrolled in a fully-insured Guardian medical plan.

13 Oct 2009

Influenza News and Research

Latest Influenza News and Research

Sinovac Biotech announces receipt of Panflu vaccine distribution approval in Hong Kong

Nobilon initiates a clinical Proof of Concept trial with SCH 900795 vaccine

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Imaging as a tool to identify severe cases of H1N1

H1N1 patients with ARDS survive illness when treated with ECMO

Statewide H1N1 Vaccine Provider Registration System from Upp Technology

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

Do not underestimate the serious impact of the H1N1 virus, say researchers

Rapid rollout of H1N1 vaccines is effective in reducing infection rates according to simulation model

American Lung Association to raise awareness about the seriousness of seasonal influenza

New Ultra Sensitive facemasks to protect against seasonal and swine flu

Studies examine H1N1 treatment, outcome differences in Mexico, Canada

NIH awards $2.2m grant to Smiths Detection to develop a test for multiple types of influenza

Study says critical illness among Canadian patients with H1N1 occurred rapidly after hospital admission

Johnson & Johnson announces financial results for the third quarter of 2009

Massive mismanagement leads to catastrophic decline in freshwater biodiversity

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

Health care workers raise troubling concern about H1N1 and seasonal flu vaccines

Cox's initiative to safeguard the community at-large

Fully-insured members of Guardian to receive 100% coverage of the administrative cost of H1N1 vaccine

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Influenza News and Research

Latest Influenza News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in